Environ Health Perspect by Braun, Joe M. et al.
Environmental Health Perspectives • volume 120 | number 5 | May 2012 739
Research | Children’s Health
Variability of Urinary Phthalate Metabolite and Bisphenol A Concentrations 
before and during Pregnancy
Joe M. Braun,1 Kristen W. Smith,1 Paige L. Williams,2 Antonia M. Calafat,3 Katharine Berry,1,4 Shelley Ehrlich,1 
and Russ Hauser1
1Department of Environmental Health, and 2Department of Biostatistics, Harvard School of Public Health, Boston Massachusetts, USA; 
3National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA; 4Division of Reproductive 
Medicine, Department of Obstetrics, Gynecology, and Reproductive Biology, Brigham and Women’s Hospital, Boston, Massachusetts USA
Background: Gestational phthalate and bisphenol A (BPA) exposure may increase the risk of 
adverse maternal/child health outcomes, but there are few data on the variability of urinary bio-
markers before and during pregnancy.
oBjective: We characterized the variability of urinary phthalate metabolite and BPA concentra-
tions before and during pregnancy and the ability of a single spot urine sample to classify average 
gestational exposure.
Methods: We collected 1,001 urine samples before and during pregnancy from 137 women who 
were partners in couples attending a Boston fertility clinic and who had a live birth. Women pro-
vided spot urine samples before (n ≥ 2) and during (n ≥ 2) pregnancy. We measured urinary concen-
trations of monoethyl phthalate (MEP), mono-n-butyl phthalate (MBP), mono-iso-butyl phthalate, 
monobenzyl phthalate (MBzP), four metabolites of di-(2-ethylhexyl) phthalate (DEHP), and BPA. 
After adjusting for specific gravity, we characterized biomarker variability using intraclass correla-
tion coefficients (ICCs) and conducted several surrogate category analyses to determine whether a 
single spot urine sample could adequately classify average gestational exposure.
results: Absolute concentrations of phthalate metabolites and BPA were similar before and during 
pregnancy. Variability was higher during pregnancy than before pregnancy for BPA and MBzP, but 
similar during and before pregnancy for MBP, MEP, and ΣDEHP. During pregnancy, MEP (ICC 
= 0.50) and MBP (ICC = 0.45) were less variable than BPA (ICC = 0.12), MBzP (ICC = 0.25), and 
ΣDEHP metabolites (ICC = 0.08). Surrogate analyses suggested that a single spot urine sample may 
reasonably classify MEP and MBP concentrations during pregnancy, but more than one sample 
may be necessary for MBzP, DEHP, and BPA.
conclusions: Urinary phthalate metabolites and BPA concentrations were variable before and 
during pregnancy, but the magnitude of variability was biomarker specific. A single spot urine 
sample adequately classified MBP and MEP concentrations during pregnancy. The present results 
may be related to unique features of the women studied, and replication in other pregnancy cohorts 
is recommended.
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Phthalates and bisphenol A (BPA) are multi­
functional compounds used in a variety of 
commercial and industrial products. Diethyl 
phthalate (DEP), di­n­butyl phthalate 
(DBP), and benzylbutyl phthalate (BzBP) 
can be used in personal care and consumer 
products to hold scent and color [National 
Research Council (NRC) 2008]. DBP, BzBP, 
and di­(2­ethyl hexyl) phthalate (DEHP) can 
also be used in the manufacture of floor­
ings, carpet backings, adhesives, wallpaper, 
and polyvinyl chloride (PVC) plastics (NRC 
2008). BPA can be used in food can linings, 
water supply pipes, medical tubing, thermal 
receipts, and cigarette filters (Biedermann 
et al. 2010; Chapin et al. 2008; Jackson and 
Darnell 1985). Exposure to BPA and phtha­
lates is nearly ubiquitous among persons in 
the United States (Calafat et al. 2008; Koch 
and Calafat 2009; Woodruff et al. 2011).
Animal studies demonstrate that gesta­
tional phthalate and BPA exposures are asso­
ciated with adverse health outcomes (Chapin 
et al. 2008; NRC 2008). Epidemiological 
studies suggest that exposure to some phtha­
lates and BPA may be associated with adverse 
neurodevelopmental outcomes (Braun 
et al. 2009; Miodovnik et al. 2011; Swan 
et al. 2010). However, the potentially epi­
sodic nature of exposure, combined with the 
short biological half­lives of these compounds 
raises questions about the adequacy of a sin­
gle spot urine sample to classify gestational 
BPA and phthalate exposure. Variations in 
the patterns of food consumption may con­
tribute to the within­person variability of 
phthalate and BPA exposure, while patterns 
of personal care product use and movement 
between environments with variable air and 
dust concentrations may create additional 
within­person variability of phthalate expo­
sure (Adibi et al. 2008; Preau et al. 2010; 
Ye et al. 2011). In addition, pregnancy­
 related changes in xenobiotic metabolism 
may contribute to the variability of urinary 
BPA and phthalate metabolite concentrations 
throughout gestation. As far as we are aware, 
no prior studies have examined the variability 
of urinary BPA and phthalate metabolite con­
centrations in the same woman before and 
during pregnancy.
A better understanding of the variability 
of urinary phthalate and BPA biomarkers can 
help investigators determine the adequacy of 
these markers to classify phthalate and BPA 
exposure during critical periods of develop­
ment such as pregnancy. The purpose of this 
study was to characterize the pattern, variabil­
ity, and reproducibility of DEHP metabo­
lites, mono­n­butyl (MBP), mono­iso­butyl 
phthalate (MiBP), mono­benzyl phthalate 
(MBzP), monoethyl phthalate (MEP), and 
BPA concentrations in serial urine samples 
from 137 women before and during preg­
nancy. In addition, we determined whether 
a single spot urine sample during the first, 
second, or third trimester could accurately 
classify average gestational phthalate and BPA 
exposure. This information will help inform 
exposure assessment in epidemiological stud­
ies and aid in the evaluation of human studies 
that use a single spot urine sample to classify 
these exposures.
Methods
Women 18–45 years of age were recruited 
from partners seeking evaluation and treat­
ment for infertility at the Massachusetts 
General Hospital (MGH) Fertility Center 
in Boston between November 2004 and 
December 2009. The present analyses were 
from a larger prospective open­cohort study, 
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the Environment and Reproductive Health 
(EARTH) Study, which was designed to 
examine the relationship between environ­
mental chemical exposures and fertility/preg­
nancy outcomes. The study was approved by 
the human studies institutional review boards 
of the MGH, Harvard School of Public 
Health and the Centers for Disease Control 
and Prevention (CDC). Subjects signed an 
informed consent form after the study proce­
dures were explained by a research nurse and 
all questions were answered.
Women included in this analysis were 
recruited pre conception (herein referred to 
as pre­ or before pregnancy) and followed 
until delivery. Conception methods included 
natural conception, ovulation induction with 
timed intercourse, intrauterine insemination, 
or in vitro fertilization. Women provided spot 
urine samples in polypropylene containers 
at enrollment, on returning for subsequent 
clinic appointments before pregnancy, and 
during pregnancy (first, second, or third 
trimester). Enrollment urine samples were 
generally collected on entry into the study 
and before fertility treatment. Before stor­
ing samples at –80°C, urine was aliquoted 
and specific gravity (SG) was measured using 
a handheld refractometer calibrated with 
deionized water before each use (National 
Instrument Company Inc, Baltimore, MD). 
Samples were shipped on dry ice to the CDC 
for analysis.
An intrauterine pregnancy was confirmed 
by presence of a fetal heartbeat detected by 
transvaginal ultrasound. We used one of three 
methods to estimate the date of conception: 
oocyte retrieval date, which was abstracted 
from medical records; crown–rump length, 
which was measured during a fetal ultrasound 
between 6 and 8 weeks of gestation; or wom­
an’s report of last menstrual period. When 
more than one dating method was available, 
priority was given to retrieval date > ultra­
sound > last menstrual period.
To examine variability of urinary phtha­
late metabolite concentration before and dur­
ing pregnancy, we restricted our analyses to 
women who delivered a liveborn infant and 
provided two or more pregnancy urine sam­
ples and two or more urine samples before 
that pregnancy. We excluded women with 
fewer than two urine samples during either or 
both time periods.
We measured the concentration of BPA 
and eight phthalate metabolites including 
MBP, MiBP, MBzP, MEP, and the following 
four DEHP metabolites: mono(2­ethyl­5­
carboxypentyl) phthalate (MECPP), mono(2­
ethyl­5­hydroxyhexyl) phthalate (MEHHP), 
mono(2­ethyl ­5­oxohexyl )  phtha late 
(MEOHP), and mono(2­ethylhexyl) phtha­
late (MEHP), using previously described ana­
lytical chemistry methods and quality control 
procedures. (Silva et al. 2007; Ye et al. 2008) 
We limited our statistical analyses to DEHP 
metabolites, MBP, MiBP, MBzP, and MEP 
because of their high frequency of detection 
in the U.S. population (Silva et al. 2004; 
Woodruff et al. 2011) The limits of detection 
(LOD) for the target phthalate metabolites 
were in the low microgram per liter range 
(~ 0.1 to ~ 1 μg/L) and 0.4 μg/L for BPA. 
Values less than the LOD were given a value 
of the LOD/√
–2 (Hornung and Reed 1990). 
We applied correction factors of 0.66 and 
0.72 to the MEP and MBzP concentrations, 
respectively, because the analytic standards 
used were of inadequate purity (Calafat A, 
personal communication).
Because DEHP is metabolized primar­
ily into MEHP, MEHHP, MECPP, and 
MEOHP, we used two summary measure­
ments: a) total molar sum of all four DEHP 
metabolites and b) molar sum of three oxida­
tive DEHP metabolites (MECPP, MEHHP, 
and MEOHP). We calculated the molar 
sum of DEHP metabolites by dividing each 
metabolite concentration by its molar mass 
and then summing the individual metabolite 
concentrations. We also present results sepa­
rately for MEHP concentrations to facilitate 
comparisons with prior studies.
We accounted for urine dilution by stan­
dardizing urinary phthalate metabolite and 
BPA concentrations using SG. Urine dilution 
was adjusted using a modified and previously 
described formula in all of our analyses of BPA 
and phthalate metabolites (Duty et al. 2005; 
Meeker et al. 2009). We excluded samples 
with SG values > 1.04 (Boeniger et al. 1993). 
All statistical analyses were conducted using 
SG­standardized biomarker concentrations 
unless otherwise noted.
Statistical analyses. Descriptive  analyses. 
We first examined the sociodemographic 
characteristics of participating women (means 
and proportions). We computed the median 
and 25th and 75th percentiles of SG­adjusted 
phthalate metabolites and BPA concentrations 
from the first (at enrollment) and last urine 
samples provided before women became preg­
nant and from samples provided during each 
trimester of pregnancy. We calculated univari­
ate characteristics of and correlation between 
the within­woman geometric mean (GM) uri­
nary phthalate metabolite and BPA concentra­
tions for all pre pregnancy and pregnancy urine 
samples. We also compared the difference in 
phthalate metabolite and BPA concentrations 
before and during pregnancy using a linear 
mixed model with log10­ transformed phtha­
late metabolite or BPA concentrations as the 
outcome. We included an indicator variable 
to designate samples as being before or during 
pregnancy. We estimated the percent differ­
ence in pregnancy concentrations relative to 
prepregnancy concentrations.
Variability analyses. We conducted three 
analyses to characterize the variability and 
change in urinary phthalate metabolite and 
BPA concentrations before and during preg­
nancy. These analyses used log10­transformed 
urinary SG­adjusted phthalate metabolite and 
BPA concentrations because of their right­
skewed distribution. First, we estimated the 
variability of urinary phthalate metabolite and 
BPA concentrations before or during preg­
nancy by calculating the intraclass correlation 
coefficient (ICC) using a random intercept­
only linear mixed model. The ICC is a mea­
sure of reproducibility, calculated by dividing 
the between­subject variability by the sum of 
the between­ and within­subject variability. 
Values range from 0, indicating no reproduc­
ibility, to 1, indicating perfect reproducibility 
(Rosner 2000). Next we estimated the percent 
change in urinary phthalate metabolite and 
BPA concentrations over time during the pre­
pregnancy or pregnancy sampling frame using 
linear mixed models with subject­ specific inter­
cepts. For pre pregnancy samples we calculated 
the number of weeks since enrollment by sub­
tracting the date of enrollment from each sub­
sequent collection date. The enrollment urine 
sample was set to a time of 0. For pregnancy 
samples, we calculated the number of weeks 
since conception for each urine sample by 
subtracting the date of conception from each 
urine sample collection date. We estimated the 
percent change in phthalate metabolite and 
BPA concentration with each 4­week change 
in time before and during pregnancy. Finally, 
using spaghetti plots, we graphed a random 
sample of urinary phthalate metabolite and 
BPA concentrations in 50 women before and 
during pregnancy as a function of time since 
enrollment or conception. 
We evaluated the pattern and variabil­
ity of urine dilution before and during preg­
nancy by conducting the above analyses using 
untransformed SG values as the outcome, 
because changes in urine dilution (i.e., SG) 
during pregnancy may partially account for 
changes in urinary phthalate concentrations.
Surrogate category analyses. We con­
ducted three additional analyses to examine 
the rank­ordering, predictive ability, and con­
sistency of a single urinary phthalate metabo­
lite and BPA concentration during pregnancy 
among women with all three urine samples 
(i.e., one sample for each trimester). First, we 
conducted a classification analysis (Hauser 
et al. 2004; Mahalingaiah et al. 2008). Using 
the GM of the three individual trimester 
phthalate metabolite or BPA concentrations, 
we calculated tertiles of average gestational 
exposure of the women. We then classified 
women into surrogate tertiles of phthalate 
metabolite/BPA concentrations using their 
trimester­specific urine sample concentration. 
We categorized the women as being either 
Urinary BPA/phthalate concentration variability
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in the top or bottom two tertiles of either 
of these measures. We then calculated the 
sensitivity, specificity, and positive predictive 
value (PPV) of the top tertile of the surrogate 
measure with the top tertile of the average 
gestational measure. The PPV is the probabil­
ity of being classified as having high average 
gestational concentrations given a high surro­
gate measure. We examined  trimester­ specific 
surrogate categories to determine if the timing 
of sample collection influenced the predictive 
ability of a single spot urine sample.
Second, we examined whether surrogate 
categories of trimester­specific urine samples 
were associated with average gestational urinary 
phthalate metabolite or BPA concentrations 
of women (Meeker et al. 2005; Teitelbaum 
et al. 2008). Similar to the first analysis, we 
calculated surrogate tertiles of  trimester­ specific 
urinary phthalate  metabolite/BPA concentra­
tions (i.e., surrogate categories of low, medium, 
and high). We then used box plots to exam­
ine the distribution of the average gestational 
exposure of women (e.g., GM of all three uri­
nary biomarker concentrations) within each 
of these surrogate categories. For example, we 
calculated the average gestational urinary BPA 
concentration of each woman using the values 
from all three trimesters. Based on the first­
trimester urinary BPA concentrations for all 
the women, we then categorized each woman’s 
first­trimester urinary BPA concentrations into 
surrogate tertiles. We then plotted the distribu­
tion of the average gestational urinary BPA 
concentration of women for the first­trimester 
surrogate tertile variable. We then completed 
the same process for the second and third tri­
mesters. If the surrogate tertile variable pro­
vides reasonable rank ordering, then we would 
expect to see increasing average gestational BPA 
concentrations across the surrogate trimester 
categories (i.e., increasing average gestational 
BPA concentration as one goes from first to 
second­ to third­trimester surrogate categories).
Finally, we examined whether the women 
remained in the same tertile of exposure over 
the course of their pregnancy by counting 
the number of times (one, two, or three) her 
urine sample concentrations were in the same 
tertile for each phthalate metabolite or BPA. 
For instance, if all three urine samples for 
a woman were in the same tertile, she was 
assigned a count of three. We calculated sepa­
rate tertiles for each trimester. All analyses 
were conducted with SAS version 9.2 (SAS 
Institute Inc., Cary, NC).
Results
Descriptive analyses. A total of 221 women in 
our study had live births. For our BPA analy­
ses, 137 women provided two or more urine 
samples (n = 636 samples) before getting preg­
nant and two or more urine samples (n = 365 
samples) during pregnancy. For phthalate 
metabolite analyses, 113 women provided 
853 samples (544 before pregnancy and 
309 during pregnancy). Women in our sample 
were predominately white, highly educated, 
and a mean (± SD) of 35 ± 4.1 years of age at 
enrollment (Table 1). The majority (59%) of 
women conceived using intrauterine insemi­
nation. Before pregnancy, women provided 
between 2 and 13 urine samples (median, 
3 samples) during a period of < 1 to 110 weeks 
after enrollment (median, 12 weeks). During 
pregnancy, a median of three samples was col­
lected. On average, first­, second­, and third­
 trimester urine samples were collected at 5 
(range, 3–12 weeks), 20 (range, 12–29 weeks), 
and 33 (range, 26–38 weeks) weeks of gesta­
tion. A median of 5 weeks elapsed between the 
last pre pregnancy and first pregnancy urine 
sample collections (range, 1–40 weeks).
Absolute concentrations of phthalate 
metabolites and BPA were essentially the same 
before and during pregnancy [Table 2; see 
Supplemental Material, Table 1 (http://dx.doi.
org/10.1289/ehp.1104139)]. The modest dif­
ferences varied by biomarkers and were highest 
for MEHP [percent difference = 29%; 95% 
confidence interval (CI): 8, 55%] and lowest 
for BPA (percent difference = 6%; 95% CI: 
–4, 17%). MEP concentrations were 19% 
lower during pregnancy compared with before 
pregnancy (95% CI: –30, –6). However, these 
differences were relatively small considering 
the variability of the analytic chemistry meth­
ods used. Correlations between concentrations 
before and during pregnancy were lower for 
the sum of DEHP metabolites (Pearson R = 
0.33), MEHP (Pearson R = 0.32), and BPA 
(Pearson R = 0.39) than for MBP (Pearson 
R = 0.62), MiBP (Pearson R = 0.55), MBzP 
(Pearson R = 0.54), and MEP (Pearson R = 
0.62) (Table 2). However, the correlation 
coefficient for MBP was attenuated (Pearson 
R = 0.45) when we excluded one woman who 
had the highest pre pregnancy (12,860 μg/L) 
and pregnancy (3,491 μg/L) urinary MBP 
concentration.
Variability analysis. Before pregnancy, 
the concentrations of DEHP metabolites, 
MBzP, BPA, and SG exhibited substantial 
within­woman variation, as evidenced by rela­
tively low ICCs (≤ 0.35) (Table 3). Graphical 
examination of urinary phthalate metabo­
lite concentrations for individual women 
over time supported this [see Supplemental 
Material, Figure 1 (http://dx.doi.org/10.1289/
ehp.1104139)]. Concentrations of MBP 
(ICC = 0.40) and MEP (ICC = 0.56) were less 
variable, but some women showed variations 
of an order of magnitude in urinary phthalate 
Table 1. Demographic characteristics of 137 women 
participating in the EARTH study included in the 
present analysis.
Demographic factor n (%)
Race
Caucasian 124 (91)
African American 2 (1)
Asian 8 (6)
Other 3 (2)
Hispanic
No 135 (99)
Yes 2 (1)
Education
< Bachelor’s degree 6 (5)
Bachelor’s degree 51 (40)
Graduate degree 70 (55)
Missing 10
Maternal age at enrollment (years)
< 30 16 (12)
30 to < 35 44 (32)
35 to < 40 61 (45)
≥ 40 16 (12)
Conception method
Natural 11 (8)
Intrauterine insemination 81 (59)
In vitro fertilization 45 (33)
Table 2. Univariate characteristics, correlations, and difference between SG-adjusted prepregnancy and 
pregnancy urinary phthalate metabolite and BPA concentrations.
Urine metabolite
GM prepregnancy 
median (25th, 
75th percentile)a
GM pregnancy 
median (25th, 
75th percentile)a Correlationb
Percent difference 
between pregnancy 
and prepregnancy 
concentration (95% CI)c
ΣDEHP metabolitesd (μmol/L) 0.33 (0.20, 0.56) 0.36 (0.18, 0.69) 0.33 9 (–8, 29)
ΣDEHP oxidative metabolitese 
(μmol/L)
0.30 (0.18, 0.52) 0.31 (0.17, 0.66) 0.34 8 (–9, 28)
MEHP (μg/L) 5.0 (2.8, 7.7) 5.9 (3.2, 13) 0.32 29 (8, 55)
MBP (μg/L) 14 (9.0, 22) 16 (11, 24) 0.62 25 (11, 41)
MiBP (μg/L) 5.4 (3.2, 8.9) 5.9 (4.0, 9.0) 0.55 9 (–4, 23)
MBzP (μg/L)f 3.2 (1.8, 5.2) 3.7 (2.0, 6.8) 0.54 22 (6, 40)
MEP (μg/L)f 61 (37, 145) 55 (24, 116) 0.62 –19 (–30, –6)
BPA (μg/L) 1.5 (1.1, 2.1) 1.5 (1.1, 2.3) 0.39 6 (–4, 17)
aMedian and percentiles of the within-woman GM of urinary phthalate metabolite or BPA concentrations in two or 
more samples obtained before pregnancy and during pregnancy. bPearson correlation coefficients between the GM 
of prepregnancy and pregnancy urinary phthalate metabolite or BPA concentrations (log10 transformed). cPercent 
difference in pregnancy versus prepregnancy urinary phthalate metabolite or BPA concentration; estimated with a 
linear mixed model with an indicator variable for pregnancy or prepregnancy (referent). dΣDEHP metabolites: mono(2-
ethyl-5-carboxypentyl) phthalate (MECPP), mono(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP), mono(2-ethyl-5-oxohexyl) 
phthalate (MEOHP), and mono(2-ethylhexyl) phthalate (MEHP). eΣDEHP oxidative metabolites: mono(2-ethyl-5-carboxy-
pentyl) phthalate (MECPP), mono(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP), and mono(2-ethyl-5-oxohexyl) phthalate 
(MEOHP). fA correction factor of 0.66 and 0.72 was applied to the MEP and MBzP concentrations, respectively.
Braun et al.
742 volume 120 | number 5 | May 2012 • Environmental Health Perspectives
metabolite concentration over time (Table 3; 
see Supplemental Material, Figure 1). Most 
of the urinary phthalate metabolite concentra­
tions exhibited similar variability both before 
and during pregnancy (Table 3). MBzP and 
BPA concentrations were more variable dur­
ing pregnancy than before pregnancy. We also 
estimated the variability of MECPP before 
and during pregnancy to determine whether a 
DEHP metabolite with a longer half­life had 
less variability than other DEHP metabolites 
(Koch et al. 2006). Similar to the other two 
summary DEHP metabolite measures, the 
variability of urinary MECPP concentrations 
was similar both before (ICC = 0.19) and dur­
ing (ICC = 0.14) pregnancy.
Overall, pre pregnancy urinary phthalate 
metabolite and BPA concentrations did not 
change over time, except for MEP and MBzP 
concentrations (Table 3). On average, uri­
nary MEP concentrations decreased 2% every 
4 weeks (95% CI: –4, 0%) before conception. 
During pregnancy, concentrations of the sum 
of the four DEHP metabolites, the sum of 
the three oxidative DEHP metabolites, and 
the concentration of the hydrolytic monoester 
MEHP all decreased over time [Table 3; see 
Supplemental Material, Figure 2 (http://
dx.doi.org/10.1289/ehp.1104139)]. The esti­
mated average decreases in MEHP concentra­
tions were larger than corresponding estimates 
for the sum of the three oxidative DEHP 
metabolites and the sum of all four DEHP 
metabolites. Decreases in urinary DEHP 
metabolite concentrations between the first 
and second trimester appeared to be respon­
sible for this trend (see Supplemental Material, 
Table 1). Because our spaghetti plots [see 
Supplemental Material, Figure 2) suggested 
that urinary DEHP metabolites decreased 
between the first and second trimester and 
then rose between the second and third trimes­
ter, we included a time­squared polynomial 
term in our model. Concentrations decreased 
54% (95% CI: –67, –37%) between the 5th 
and 20th week of gestation and increased 18% 
(95% CI: –13, 62%) between the 20th and 
33rd week of gestation. Urinary concentra­
tions of MBP, MBzP, and SG did not change 
over time during pregnancy, but MEP concen­
trations rose slightly during pregnancy (3%; 
95% CI: –1, 7%) (Table 3).
Surrogate category analysis. In our classifi­
cation analysis using the GM concentration of 
urinary phthalate metabolites as the assumed 
gold standard of gestational exposure, the top 
tertile of trimester­specific phthalate metabo­
lite and BPA concentrations accurately classi­
fied the highest tertile of gestational exposure 
in at least 54% of women (Table 4). The PPVs 
varied across trimesters for phthalate metabo­
lites and BPA. For instance, PPVs were highest 
for BPA concentrations in the first trimester 
(PPV = 0.70), but lowest in the second trimes­
ter (PPV = 0.60). Second­ and third­trimester 
concentrations of MBP and MEP accurately 
classified ≥ 69% of women. Classification 
probabilities for the sum of DEHP metabo­
lites and oxidative DEHP metabolites were 
similar to MEHP.
We observed that average gestational uri­
nary phthalate metabolite/BPA concentrations 
increased across tertiles of trimester­specific 
concentrations (Figure 1). Average gestational 
phthalate metabolite/BPA concentrations were 
lowest among participants with trimester­
specific samples classified in the lowest tertile 
and highest among women in the top tertiles. 
However, the range of average gestational con­
centrations between adjacent surrogate cate­
gories overlapped in at least one trimester for 
each phthalate metabolite and BPA.
In our final surrogate analysis, at least 77% 
of women had two or more urine samples in 
the same tertile of urinary phthalate metabo­
lite or BPA concentrations during the course 
of pregnancy (Table 5). The proportion of 
women with all three urine samples in the 
same category during each trimester ranged 
from 16% (for DEHP) to 26% (for MBP).
Table 3. Intraclass correlation coefficients for and percent change (per 4 weeks) in SG–adjusted urinary 
phthalate metabolite/BPA concentrations and SG before and during pregnancy.
Before pregnancy During pregnancy
Urinary metabolite ICCa
Percent change per 
4 weeks (95% CI)b ICCa
Percent change per 
4 weeks (95% CI)b
ΣDEHP metabolitesc (μmol/L) 0.11 –1 (–3, 2) 0.08 –8 (–13, –4)
ΣDEHP oxidative metabolitesd (μmol/L) 0.12 –1 (–3, 1) 0.09 –8 (–13, –4)
MEHP (μg/L) 0.11 0 (–2, 3) 0.08 –13 (–17, –8)
MBP (μg/L) 0.40 0 (–1, 2) 0.45 –1 (–4, 3)
MiBP (μg/L) 0.36 0 (–2, 2) 0.38 3 (0, 6)
MBzP (μg/L)e 0.35 2 (0, 4) 0.25 –1 (–4, 4)
MEP (μg/L)e 0.56 –2 (–4, 0) 0.50 3 (–1, 7)
BPA (μg/L) 0.23 0 (–1, 1) 0.12 –1 (–4, 2)
SG 0.27 0.0000 (–0.0001, 0.0002) 0.37 –0.0002 (–0.0004, 0.000)
aLog10-transformed metabolite concentrations (except SG) are the outcome in a linear mixed model with a random 
intercept and the time in weeks since enrollment or conception as the predictor. bLog10-transformed metabolite con-
centrations (except SG) are the outcome in a linear mixed model with a random intercept. cΣDEHP metabolites: mono(2-
ethyl-5-carboxypentyl) phthalate (MECPP), mono(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP), mono(2-ethyl-5-oxohexyl) 
phthalate (MEOHP), and mono(2-ethylhexyl) phthalate (MEHP). dΣDEHP oxidative metabolites: mono(2-ethyl-5-carboxy-
pentyl) phthalate (MECPP), mono(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP), and mono(2-ethyl-5-oxohexyl) phthalate 
(MEOHP). eA correction factor of 0.66 and 0.72 was applied to the MEP and MBzP concentrations, respectively.
Table 4. Classification probabilities for the top tertile of average gestational BPA or phthalate concentration 
according to trimester-specific surrogate categories.a,b
Urinary metabolite
33rd 
percentile
66th 
percentile Sensitivity Specificity PPVc
ΣDEHP (μmol/L)d
First 0.22 0.89 0.69 0.84 0.69
Second 0.17 0.33 0.54 0.76 0.54
Third 0.15 0.45 0.62 0.80 0.62
MBP (μg/L)
First 11 21 0.62 0.80 0.62
Second 12 23 0.73 0.86 0.73
Third 12 22 0.69 0.84 0.69
MBzP (μg/L)
First 2.7 5.4 0.65 0.82 0.65
Second 2.3 5.1 0.62 0.80 0.62
Third 2.3 5.3 0.69 0.84 0.69
MEP (μg/L)
First 20 73 0.62 0.80 0.62
Second 33 85 0.81 0.90 0.81
Third 28 81 0.77 0.88 0.77
BPA (μg/L)
First 1.1 2.1 0.70 0.85 0.70
Second 1.0 1.9 0.60 0.80 0.60
Third 1.0 2.0 0.67 0.84 0.67
aAssumes that the within-woman GM gestational urinary phthalate or BPA concentration is the gold standard. The sur-
rogate measure of low, medium, or high is defined by the first, second, or third tertile of trimester-specific urine samples, 
respectively. Probabilities are calculated from the top versus bottom two tertiles of trimester-specific and average 
gestation urinary phthalate metabolite and BPA concentrations. Limited to women with all three urine samples. All con-
centrations are SG adjusted. bn = 77 for phthalates; n = 91 for BPA. cPPV is the probability of being classified in the top 
tertile of mean gestational phthalate metabolite or BPA concentration, given that the woman’s trimester-specific urinary 
phthalate metabolite or BPA concentration is in the top tertile. dΣDEHP metabolites: mono(2-ethyl-5-carboxypentyl) 
phthalate (MECPP), mono(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP), mono(2-ethyl-5-oxohexyl) phthalate (MEOHP), 
and mono(2-ethylhexyl) phthalate (MEHP).
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Discussion
The absolute differences in urinary concentra­
tions of DEHP metabolites, MBP, MiBP, 
MBzP, and BPA were relatively small before 
and during pregnancy, considering the vari­
ability of our analytic chemistry methods. 
Urinary concentrations of MBP, MBzP, and 
MEP were modestly correlated before and 
during pregnancy, whereas DEHP metabolites 
and BPA were less correlated during the two 
time periods. Serial urine concentrations of 
BPA and some phthalate metabolites were 
highly variable before and during pregnancy. 
The variability of most urinary phthalate 
metabolites was similar before and during 
pregnancy, whereas the variability of BPA and 
MBzP increased during pregnancy. During 
pregnancy, urinary concentrations of DEHP 
metabolites decreased and were the most vari­
able. MBP and MEP concentrations were less 
variable, and MEP and MiBP concentrations 
increased during pregnancy.
The variability of urinary phthalate metabo­
lite and BPA concentrations in our study par­
ticipants was remarkably similar to that of 
most previous studies that collected multiple 
urine samples over weeks to months from 
Figure 1. Box plots of average gestational SG-adjusted urinary phthalate metabolite or BPA concentrations according to trimester-specific tertiles. Surrogate 
 measures (first, second, or third trimester) were divided into tertiles. The displayed values are the minimum (bottom whisker), 25th percentile (bottom of box), 
median (line in box), mean (diamond), 75th percentile (top of box), and maximum (top whisker) of the average gestational urinary phthalate and BPA concentra-
tions. Limited to women with all three pregnancy urine samples. All concentrations are SG adjusted. n = 77 for phthalate analysis; n = 91 for BPA analysis. DEHP 
metabolites: mono(2-ethyl-5-carboxypentyl) phthalate (MECPP), mono(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP), mono(2-ethyl-5-oxohexyl) phthalate (MEOHP), and 
mono(2-ethylhexyl) phthalate (MEHP).
Surrogate: 1st trimester Surrogate: 2nd trimester Surrogate: 3rd trimester Surrogate: 1st trimester Surrogate: 2nd trimester Surrogate: 3rd trimester
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the same individuals (Adibi et al. 2008; Baird 
et al. 2010; Braun et al. 2011; Hauser et al. 
2004; Irvin et al. 2010; Peck et al. 2010). 
Previous studies of phthalate metabolites have 
all shown a similar pattern where the con­
centration of MEHP is the most variable and 
concentrations of MBP, MEP, and MBzP 
are less variable. MEP concentrations (ICC 
= 0.21) among pregnant women from New 
York City were more variable than MEP con­
centrations in our study participants (Adibi 
et al. 2008). Source population characteristics 
and variations in exposure sources could influ­
ence within­woman variability across cohorts.
To our knowledge, no studies have exam­
ined whether phthalate metabolite and BPA 
concentrations or their within­person variabil­
ity are different before or during pregnancy in 
the same woman. Differences would suggest 
that physiological changes during pregnancy 
may influence the absorption, distribution, 
metabolism, or excretion of phthalate metabo­
lites and BPA. The absolute differences in 
urinary concentrations of phthalate metabo­
lites and BPA were relatively small, suggesting 
that women did not change their behaviors to 
reduce these exposures. We did not observe 
a consistent increase or decrease in most 
phthalate metabolites or BPA over the course 
of pregnancy, which suggests that urinary 
concentrations of these compounds are not 
impacted by pregnancy­induced changes in 
pharmacokinetics. However, urinary concen­
trations of DEHP metabolites decreased dur­
ing pregnancy. Behavioral changes may be 
responsible for the decrease in urinary DEHP 
metabolite concentrations between the first 
and second trimesters of pregnancy, because 
women may have begun eating more meals 
consisting of fresh foods with less packag­
ing after learning of their pregnancy (Rudel 
et al. 2011).
The different variability among urinary 
phthalate metabolite and BPA concentra­
tions may be attributable to their exposure 
sources. Diet is believed to be the main source 
of DEHP and BPA exposure, primarily from 
PVC materials used in the processing/ storage 
of food and polycarbonate food/ beverage 
containers, respectively (Chapin et al. 2008; 
Lopez­Cervantes and Paseiro­Losada 2003; 
Petersen and Jensen 2010; von Goetz et al. 
2010). Other sources of BPA exposure may 
include contact with thermal receipts (Braun 
et al. 2011; Liao and Kannan 2011). Higher 
day­to­day and within­day variability in 
dietary sources is likely responsible for the 
higher variability of urinary DEHP metabo­
lites and BPA concentrations relative to MEP 
and MBP concentrations, whose primary 
sources include personal care and beauty 
products (Preau et al. 2010; Ye et al. 2011). 
Although the half­lives of the DEHP metabo­
lites vary, we observed similar variability of 
both MEHP and MECPP, suggesting that 
the sources of exposure may be more impor­
tant than half­life of the metabolite.
MEP and MBP concentrations were rela­
tively stable and reproducible in repeated sam­
ples collected before and during pregnancy. 
Preau et al. (2010) reported that urinary MEP 
concentrations among eight adult volunteers 
were variable during the day but exhibited 
similar patterns across days within the same 
individual. One possible explanation may be 
that people use the same DBP­ and DEP­
containing personal care or cosmetic products 
from day to day and at similar times during 
the day, which may be responsible for the 
reduced variability in DBP and DEP urinary 
metabolites relative to other phthalate metab­
olites (Duty et al. 2005; Romero­Franco 
et al. 2011). Furthermore, phthalates found 
in personal care products will be absorbed 
across the skin over a longer period of time 
and bypass first­pass metabolism in the liver, 
which might increase their apparent half­life 
and reduce the variability of their metabolite 
concentrations in urine within a given day.
Our results suggest that MEP and MBP 
concentrations measured in a single spot 
urine sample in the second or third trimester 
of pregnancy might reasonably classify gesta­
tional exposure to DEP and DBP, respectively. 
However, reproducibility was substantially 
lower in samples collected in the first trimes­
ter. Given that DEHP metabolites, MBzP, 
and BPA were more variable, more than one 
sample may be necessary to adequately clas­
sify gestational exposure to these compounds. 
Most sampling strategies will not completely 
eliminate all variability and will still result in 
some exposure misclassification.
Our surrogate category analysis has at least 
two limitations. First, we assumed that GM 
phthalate metabolite and BPA concentrations 
from three urine samples during pregnancy 
were indicative of exposure during the entire 
gestation. However, it is likely that there were 
additional exposures and sources of exposure 
variability that we were unable to capture. 
Serial urine collections will not be possible in 
every epidemiological study, and researchers 
are encouraged to conduct their own expo­
sure validation when possible. Second, our 
surrogate analyses may overestimate the accu­
racy of a single spot urine sample because of 
the non independence of the surrogate and 
average measures. Other studies with more 
than three urine samples during pregnancy 
are needed to determine whether a single spot 
urine sample, not included in the calculation 
of average exposure, can accurately classify 
gestational exposure.
The primary strength of this study was 
the availability of multiple urine samples 
obtained both before and during pregnancy 
from the same woman. Furthermore, we col­
lected urine samples very early in pregnancy, 
allowing us to examine exposures and expo­
sure variability across the entire pregnancy. 
However, we were not able to examine BPA 
and phthalate metabolite variability within 
specific trimesters, which may be important in 
identifying critical windows of exposure dur­
ing pregnancy. Depending on the end point 
of interest, it may be more relevant to classify 
exposure during a narrow window of gesta­
tion early in pregnancy instead of during the 
entire period of gestation (Ge et al. 2007). 
Although we were unable to estimate variabil­
ity within narrower windows of gestation, our 
findings may be used to guide and evaluate 
studies examining gestational phthalate/BPA 
exposures and maternal/child health outcomes. 
Given the consistent magnitude of phthalate 
metabolite/BPA variability observed in previ­
ous studies conducted over time spans ranging 
from days to months, we believe the variability 
within trimesters or narrower windows would 
be similar to the variability over the course of 
pregnancy, especially considering the short 
half­life and non persistent nature of phthalates 
and BPA (Adibi et al. 2008; Baird et al. 2010; 
Braun et al. 2011; Hauser et al. 2004; Irvin 
et al. 2010; Peck et al. 2010; Preau et al. 2010; 
Ye et al. 2011).
Source population characteristics could 
influence phthalate/BPA exposures and their 
absorption, distribution, metabolism, and 
excretion. Therefore, these results may not be 
generalizable to other populations. Women 
in this study were from higher socioeconomic 
position and were aware that this study was 
examining the health effects of phthalates and 
other environmental chemicals. These factors 
might increase the likelihood of behavioral 
changes before and during pregnancy that 
would not be observed in other source popu­
lations. In addition, these women were older 
than women from studies among couples con­
ceiving naturally and were partners in couples 
Table 5. Number (%) of women with individual spot urine samples in the same tertile of exposure during 
pregnancy.a
No. of samples  
in the same tertile
ΣDEHP 
metabolitesb MBP MBzP MEP BPA
None 16 (21) 18 (23) 16 (21) 16 (21) 16 (18)
2 49 (64) 39 (51) 49 (64) 48 (62) 54 (59)
3 12 (16) 20 (26) 12 (16) 13 (17) 21 (23)
aLimited to women with all three pregnancy urine samples (n = 77 for phthalate analysis; n = 91 for BPA analysis). bDEHP 
metabolites: mono(2-ethyl-5-carboxypentyl) phthalate (MECPP), mono(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP), 
mono(2-ethyl-5-oxohexyl) phthalate (MEOHP), and mono(2-ethylhexyl) phthalate (MEHP). 
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seeking treatment for infertility. Physiological 
changes associated with advanced age or sub­
fertility may be responsible for some of the 
observed results in this cohort.
In conclusion, urinary phthalate metabo­
lite and BPA concentrations were variable 
before and during pregnancy in this cohort. 
MEP and MBP concentrations were less vari­
able and more correlated before and during 
pregnancy than DEHP metabolites, MBzP, 
and BPA. Our findings suggest that a single 
spot urine sample may permit relatively accu­
rate classification of DBP and DEP exposure 
during pregnancy, but accurate classification 
of DEHP, BzBP, and BPA exposure may 
require multiple urine samples. Our variabil­
ity and surrogate category estimates can be 
used to assess the extent to which phthalate 
and BPA exposure misclassification may bias 
results in epidemiological studies. Future 
studies should investigate the relative contri­
bution of pharmacokinetic and behavioral 
factors to urinary phthalate metabolite and 
BPA concentration variability.
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ERRATUM
Environmental Health Perspectives • ERRATUM 
NOTE: Braun et al. discovered an error in the SAS code of their paper “Variability of Urinary Phthalate Metabolite and Bisphenol A 
Concentrations before and during Pregnancy” [Environ Health Perspect 120:739–745 (2012)]. The error resulted in the reported absolute 
concentrations of phthalate metabolites and BPA being approximately 50% higher. The authors mistakenly used the median value from the 
EARTH study men [specific gravity (SG) = 1.025] rather than women (SG = 1.015) in their SG calculations. Thus, the reported concentra-
tions in Table 2 (columns 2 and 3), Table 4 (columns 2 and 3), and Figure 1, as well as in the Supplemental Material, were higher than if 
the median SG for this group of women had been used. The authors note that this error did not alter the statistical analyses or their inter-
pretations or the conclusions of their paper. 
The authors regret the errors.
The corrected text is presented in the PDF version of this article.
